Projects

The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy.The imSAVAR is an Innovative Medicines Initiative funded project that aims to develop a standard for integrated nonclinical safety overviews for immune-modulatory investigational new drugs (IND) and clinical trial applications (CTA).Our imSAVAR platform will improve the prediction of the transferability of safety and efficacy of immunomodulators ...

Analysis of the humoral response against HLA alloantigens is performed using museal methods. With the use of AI we aim to predict deleterious antibody production avoiding allograft deterioration and graft loss.

MMML-MYC-SYS is a interdisciplinary consortium where partners from clinical haemaoncological study groups, pathologists, geneticicts, cell biologists as well as mathematicians, statisticians and bioinformaticists have allied. The goal is to investigate the process of development of B-cell lymphoma under special consideration of mutation of MYC. MYC is known to support the development and growth of tumors. This consortium collected and evaluated comprehensive molecular-genetic data for this purpose. ...

The Leipzig Melanoma Studies project consists of studies of the Department of Dermatology, Venereology and Allergology (Leipzig University), Interdisciplinary Center for Bioinformatics (IZBI, Leipzig University) and the Max Planck Institute for Evolutionary Anthropology Leipzig. Single cell transcriptome analyses of melanoma cases and cultures where preformed in the studies.

B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study ...